dm+d

Unassigned

Medicine Compliance Aid Stability

genericVarious generic versions

Various generic versions
generic
Tablets sublingual 300 micrograms, 500 micrograms, 600 micrograms
R1 · Red 1Stability data indicates that the drug is not suitable for CAs.
Unsuitable
Sublingual tablet, unsuitable for MCA.
9 November 2015

Lactation Safety Information

Rectal

Rectal
Yes
-
Limited published evidence of safety
Mothers should be advised to breastfeed the infant immediately before application of the ointment and to try to avoid breastfeeding for 1-2 hours after use to minimise infant exposure
11 July 2016

Buccal tablets / Parenteral / Transdermal

Buccal tablets / Parenteral / Transdermal
-
No published evidence of safety
Caution applies to chronic use. However, considered safe for short-term use
Monitor infants for flushing after feeding if shorter-acting formulations used
12 May 2017

Sublingual (Tablets / Spray)

Sublingual (Tablets / Spray)
Yes
-
No published evidence of safety
Sublingual use (tablets/spray) preferred to other formulations
12 May 2017

New Medicines

Erectile dysfunction, first-line - topical gel formulation using DermaSys technology

Information

New formulation
Future Medical Developments
Not Known

Development and Regulatory status

None
Phase III Clinical Trials
None

Category

Topical nitrate applied using DermaSys technology, induces dilation of the cavernous and helicline arteries, thereby increasing blood flow to the lacunar spaces, coupled with nitrate-induced relaxation of trabecular smooth muscle.
The first large-scale community study - the Massachusetts Male Ageing Study - showed that 52% of men (aged 40-70 years) were affected at some time (mild 17%; moderate 25%; severe 10%). A Cologne study reported that ED was the most prevalent of the male sexual dysfunctions (prevalence age 30-80 years) at 19.2% vs. 31% for all types of male sexual dysfunction. This study equates to about 26 new cases annually per 1,000 men [1].
Erectile dysfunction, first-line - topical gel formulation using DermaSys technology
Topical

Evidence based evaluations